Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
Macerich Co (NYSE:MAC)’s shares picked up 5.10%, and closed at $88.07. The stock has the beta value of 1.02, and its volatility for the week is 2.24%, while for the month it is 1.92%. The company has the market capitalization of $13.93B. The mean recommendation of analysts for this stock is 3.00.(where 1=Buy, 5=Sale).
The Macerich Corporation is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It primarily engages in attainment, ownership, development, redevelopment, administration and leasing of regional and community shopping centers located throughout the United States. The Macerich Corporation was founded in 1964 and is headquartered in Santa Monica, California.
Medivation Inc (NASDAQ:MDVN), raised 5.02%, and closed at $127.08, hitting new 52-week high of $129.49.
Formerly on February 25, Medivation, Inc. (MDVN), stated its financial results for the fourth quarter and year ended December 31, 2014. U.S. net sales of XTANDI® (enzalutamide) capsules, as stated by Astellas Pharma Inc., were $230.2 million for the quarter (+82% vs. preceding year) and $679.8 million for the full year 2014 (+73% vs. preceding year). Fourth quarter U.S. net sales raised about 27% contrast to third quarter net sales of $181.4 million. As formerly revealed, an estimated 80% of the sequential quarter percentage raise represents underlying demand growth, following the September approval of the metastatic castration resistant prostate cancer (CRPC) chemotherapy-naive indication. Based on information offered by Astellas, XTANDI U.S. net sales for the quarter ended December 31, 2014 comprised of a $3.8 million favorable gross-to-net adjustment, as recorded by Astellas, and an raise in channel partner inventory of about one week, also as formerly anticipated and revealed.
Ex-U.S. net sales of XTANDI, as stated by Astellas, were about $126 million for the quarter (+246% vs. preceding year) and about $381 million for the full year 2014 (+622% vs. preceding year). Fourth quarter ex-U.S. net sales raised by 5% contrast to third quarter net sales of about $120 million. U.S. dollar equivalent net sales for the fourth quarter were adversely affected by about 7%, due to a strengthening of the U.S. dollar, against the euro and yen primarily, contrast with the third quarter.
Medivation, Inc. (MDVN), is a biopharmaceutical corporation focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options.
TG Therapeutics Inc (NASDAQ:TGTX), enhanced 4.98%, and closed at $15.59.
TG Therapeutics Inc (NASDAQ:TGTX) Release: Coronado Biosciences, Inc., (CNDO) declared the formation of a new partner corporation, Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (Dana-Farber). Dr. Marasco will chair the Scientific Advisory Board of the Corporation. Under the terms of the contract, Checkpoint will pay Dana-Farber an up-front licensing fee in addition to development and sales-based milestone payments and royalties on net sales.
In connection with the license contract with Dana-Farber, Checkpoint Therapeutics reached a partnership contract with TG Therapeutics, Inc. (TGTX), to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint retains the right to develop and commercialize these antibodies in solid tumors. Both programs are presently in pre-clinical development. Under the terms of the contract, TG Therapeutics will pay Checkpoint an up-front licensing fee in addition to make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), enhanced 4.94%, and closed at $1.70.
Navidea Biopharmaceuticals, Inc (NAVB), declared results for the fourth quarter and year ended December 31, 2014. Navidea stated total proceed for 2014 of $6.3 million counting Lymphoseek® (technetium Tc 99m tilmanocept) injection sales proceed of $4.2 million. Projected guidance for Navidea’s share of Lymphoseek proceed in 2015 is $10 million to $12 million. Based on predictable proceed run rates and consistent with proceed guidance, Navidea anticipates to achieve break-even cash flow in first quarter 2016 based on our current planned plans.
Financial Results:
Full Year Financial Results:
Proceeds for the year ended December 31, 2014 were $6.3 million contrast to $1.1 million for 2013. Navidea’s proceeds for 2014 comprised of $4.2 million in sales of Lymphoseek, $300,000 from business development milestones and $1.7 million from various federal grants and other proceed, contrast to $614,000, $0 and $516,000, respectively, for 2013.
Operating expenses for the year ended December 31, 2014 were $32.3 million contrast to $39.2 million for 2013. Research and development expenses were $16.8 million during 2014 contrast to $23.7 million during 2013. The net decrease from 2013 to 2014 was primarily a result of reductions in Lymphoseek, NAV5001 and NAV4694 product development costs coupled with reduced headcount. Selling, general and administrative expenses were $15.5 million for 2014 and 2013. Raised medical education costs, legal and professional services and other support costs were offset by reduced investor relations costs, compensation, and out-of-pocket marketing costs to support the commercial launch of Lymphoseek.
Navidea’s loss from operations for the year ended December 31, 2014 was $27.6 million contrast to $38.4 million for the same period in 2013. For the year ended December 31, 2014, Navidea stated a loss attributable to ordinary stockholders of $35.7 million, or $0.24 per share, contrast to a loss attributable to ordinary stockholders of $42.7 million, or $0.35 per share, for the same period in 2013.
